ERBB2 and breast cancer: Trastuzumab, as the initial monoclonal antibody targeting HER-2, has gained approval for the remedy of HER2-positive BC, imparting significant enhancements to long-term survival and disease-free maintenance (Jagosky and Tan, 2021).